Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tesaro
Pharma
In royalty dispute, UK appeals court sides with GSK over AZ
GSK was previously ordered to pay AstraZeneca a larger share of total sales on its PARP inhibitor Zejula. But now the decision is reversed.
Zoey Becker
Feb 14, 2024 8:22am
AZ wins royalties case against GSK over PARP inhibitor Zejula
Apr 5, 2023 7:11pm
GSK cancer unit, in 'building mode,' gets picky with M&A
Jan 17, 2020 12:40pm
With Tesaro expertise, GSK gears up for 3 oncology launches
Jan 14, 2020 3:05pm
GSK's Zejula racks up first-line ovarian cancer maintenance win
Jul 15, 2019 9:44am
GSK's Tesaro taps Scott Foley on ovarian cancer maintenance push
Mar 6, 2019 10:24pm
